BUZZ-: Kite Pharma Inc: Lead cancer drug shows promise in trial

Mon Aug 25, 2014 5:35pm EDT

** Cancer drug developer's shares up 31.2 pct at $29.25 in extended trade

** Says its lead drug has potential to treat aggressive form of blood cancer

** The therapy, KTE-C19, involves genetically modifying a patient's T cells, and is designed to target a protein expressed on the cell surface of some lymphomas and leukemias

** Company says results support investigational new drug application for KTE-C19

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.